

CURRICULUM
VITAE
MATTÉO
TEBALDI

INFORMAZIONI PERSONALI

Nome Matteo Tebaldi
Indirizzo
Telefono
E-mail
Data di nascita

ISTRUZIONE

Titolo
Conseguita presso
Data
Titolo
Conseguita presso
Data

ESPERIENZE LAVORATIVE

- Data Da Luglio 2013 a Ottobre 2013
- Azienda Ospedale S. Giacomo Castelfranco Veneto
- Reparto U.O di Cardiologia
- Qualifica Cardiologo interventista
- Data Novembre 2013 a oggi
- Azienda Azienda ospedaliero Universitaria di Ferrara
- Reparto U.O. di Cardiologia
- Qualifica Cardiologo interventista

INTERESSI DI RICERCA

Cardiologia interventistica
Fractional flow reserve (FFR)
Microcircolo coronarico
Terapia antiplastrinica

Competenze

MADRELINGUA Italiano

ALTRE LINGUE

- lettura Inglese e Francese
- scrittura Buono
- parlato Buono

INSEGNAMENTO

Docente della Scuola di specializzazione "Malattia dell' Apparato Cardiovascolare" presso l' Università degli studi di Ferrara

PROFILO SCIENTIFICO	- indice H:21; I10 Index:35 - Autore di 50 articoli pubblicati su riviste internazionali (JACC, EHJ, IJC, Lancet) investigatore in numerosi trial randomizzati internazionali (es. Examination , Regulate-PCI, Complete, Global Leaders-matrix- RAD-Matrix) - Vincitore come Co-PI di Unità del "Bando di ricerca finalizzata del 2014/2015" categoria giovani ricercatori, con uno studio dal titolo "Angiographic control vs. ischemia-driven management of Patients undergoing percutaneous revascularization of the Unprotected Left main coronary artery with Second-generation drug Eluting stents PULSE"
LIST OF PUBLICATIONS	1. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, <u>Tebaldi M</u>, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet</i>. 2018 Sep 8;392(10150):835-848. 2. Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, <u>Tebaldi M</u>, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Bøtker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. <i>J Am Heart Assoc</i>. 2018 Jul 6;7(14) 3. <u>Tebaldi M</u>, Biscaglia S, Tumscitz C, Del Franco A, Gallo F, Spitaleri G, Fileti L, Serenelli M, Tonet E, Erriquez A, Campo G, Ferrari R Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. <i>Cardiology</i>. 2018;140(2):74-82 4. <u>Tebaldi M</u>, Biscaglia S, Campo G. Low FFR equal to low ischemia: Really? <i>International Journal of Cardiology</i> 265 (2018) 81 5. <u>Tebaldi M</u>, Biscaglia S, Fineschi M, Musumeci G, Marchese A, Leone AM, Rossi ML, Stefanini G, Maione A, Menozzi A, Tarantino F, Lodolini V, Gallo F, Barbato E, Tarantini G, Campo G. Evolving Routine Standards in Invasive Hemodynamic Assessment of Coronary Stenosis: The Nationwide Italian SICI-GISE Cross-Sectional ERIS Study. <i>JACC Cardiovasc Interv</i>. 2018 May 17. 6. Secco GG, <u>Tebaldi M</u>, Parisi R, Cuculo A, Di Mario C, Sangiorgio P, Ielasi A, Centola A, Fattori R, Vercellino M, Longo G, Pistis G, Biscaglia S, Ruggiero A, Marino PN, Campo G. One-Year Clinical Outcomes of Forty-Eight Millimeter Everolimus-Eluting Stent Implanted in Very Long Lesions: A Propensity-Matched Comparison (The FREIUS Study). <i>J Invasive Cardiol</i>. 2018 Apr;30(4):133-137. 7. Gallo F, <u>Tebaldi M</u>, Tumscitz C. [Antegrade and retrograde approach through the venous graft for treating a chronic total occlusion in a patient with acute coronary syndrome complicated by pulmonary edema]. <i>G Ital Cardiol (Rome)</i>. 2018 Jan;19(1):67-70 8. Spitaleri G, <u>Tebaldi M</u>, Biscaglia S, Westra J, Brugaletta S, Erriquez A, Passarini G, Brieda A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Trani C, Ferrari R, Reiber JHC, Valgimigli M, Sabatè M, Campo G. <i>Circ Cardiovasc Interv</i>. 2018 Feb;11(2):e006023 9. Sciahbasi A, Frigoli E, Sarandrea A, Calabrò P, Rubartelli P, Cortese B, Tomassini F, Zavalloni D, <u>Tebaldi M</u>, Calabria P, Rigattieri S, Zingarelli A, Sardella G, Lupi A, Rothenbühler M, Heg D, Valgimigli M. <i>Am Heart J</i>. 2018 Feb;196:113-118 10. Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Viecei Dalla Sega F, <u>Tebaldi M</u>, Tumscitz C, Ferrari R, Campo G. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. <i>PLoS One</i>. 2017 Aug 23;12(8):e0182124 11. Tumscitz C, Campo G, <u>Tebaldi M</u>, Gallo F, Pirani L, Biscaglia S. Safety and

- Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty: A Pilot Study. *JACC Cardiovasc Interv.* 2017 Jul 10;10(13):1375-1377
12. Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabrò P, Lupi A, Tomassini F, Cortese B, Rigattieri S, Cerrato E, Zavalloni D, Zingarelli A, Calabria P, Rubartelli P, Sardella G, Tebaldi M, Windecker S, Jüni P, Heg D, Valgimigli M. Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial. *J Am Coll Cardiol.* 2017 May 23;69(20):2530-2537
 13. Piccolo R, Magnani G, Ariotti S, Gargiulo G, Marino M, Santucci A, Franzone A, Tebaldi M, Heg D, Windecker S, Valgimigli M. Ischemic and Bleeding Outcomes in Elderly Patients Undergoing a Prolonged versus Shortened Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention. Insights from the PRODIGY randomized trial. *EuroIntervention.* 2017 Jan 3;12(13). pii: EIJ-D-16-00497. doi: 10.4244/EIJ-D-16-00497
 14. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden L, Reiber J, Holm N, Wijns W. TCT-11 Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve from Diagnostic Coronary X-ray Angiography in the International Multicenter FAVOR (Functional Assessment by Various FLOW Reconstructions) Pilot Study. *J Am Coll Cardiol.* 2016 Nov 1;68(18S):B5. doi: 10.1016/j.jacc.2016.09.888.
 15. De Maria GL, Fahrni G, Alkhalil M, Cuculi F, Dawkins S, Wolfrum M, Choudhury RP, Forfar JC, Prendergast BD, Yetgin T, van Geuns RJ, Tebaldi M, Channon KM, Kharbanda RK, Rothwell PM, Valgimigli M, Banning AP. A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score) *EuroIntervention.* 2016 Nov 20;12(10):1223-1230. doi: 10.4244/EIJV12I10A202
 16. Biscaglia S, Tebaldi M, Tumscitz C, Pavasini R, Marchesini J, Gallo F, Spitaleri G, Zaraket F, Serenelli M, Cimaglia P, Bugani G, Campo G. Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. *Circ J.* 2016 Dec 22;81(1):82-89. doi: 10.1253/circj.CJ-16-0785.
 17. Biscaglia S, Campo G, Pavasini R, Tebaldi M, Tumscitz C, Ferrari R. Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. *Platelets.* 2016 Jul;27(5):484-7. doi: 10.3109/09537104.2015.1119815
 18. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv.* 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013
 19. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M; ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. *JACC Cardiovasc Interv.* 2016 Mar 14;9(5):426-36. doi: 10.1016/j.jcin.2015.11.015
 20. Tebaldi M, Biscaglia S, Pecoraro A, Fineschi M, Campo G. Fractional flowreserve implementation in daily clinical practice: A European survey. *Int J Cardiol.* 2016 Jan 9;207:206-207. doi: 10.1016/j.ijcard.2016.01.097
 21. Tebaldi M, Biscaglia S, Fineschi M, Manari A, Menozzi M, Secco GG, Di Lorenzo E, D'Ascenzo F, Fabbian F, Tumscitz C, Ferrari R, Campo G. Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multi center Italian registry (the FREAK study). *Catheter Cardiovasc Interv.* 2015 Dec 31. doi: 10.1002/ccd.26364.
 22. Biscaglia S, Campo G, Tebaldi M, Tumscitz C, Pavasini R, Fileti L, Secco GG, Di Mario C, Ferrari R. Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. *Int J Cardiovasc Imaging.* 2016 Feb;32(2):211-23. doi: 10.1007/s10554-015-0756-1. Epub 2015 Sep 1.

23. Tebaldi M, Campo G, Biscaglia S. Fractional flow reserve: Current applications and overview of the available data. *World J Clin Cases*. 2015 Aug 16;3(8):678-81. doi: 10.12998/wjcc.v3.i8.678.
24. Campo G, Pavasini R, Biscaglia S, Ferri A, Andrenacci E, Tebaldi M, Ferrari R. Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascode treatment. A randomized study. *Pharmacol Res*. 2015 Jul;97:1-6. doi: 10.1016/j.phrs.2015.03.020
25. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airolidi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol*. 2015 Mar 3;65(8):805-15. doi: 10.1016/j.jacc.2014.11.053.
26. Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M, Biscaglia S, Valgimigli M. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. *Catheter Cardiovasc Interv*. 2015 Jul;86(1):E19-27. doi: 10.1002/ccd.25822.
27. Tumscitz C, Pirani L, Tebaldi M, Campo G, Biscaglia S. Seven french radial artery access for PCI: a prospective single-center experience. *Int J Cardiol*. 2014 Oct 20;176(3):1074-5. doi: 10.1016/j.ijcard.2014.07.134.
28. Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV, Mehran R, Valgimigli M. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. *Eur Heart J*. 2014 Oct 1;35(37):2524-9. doi: 10.1093/eurheartj/ehu161.
29. Sciahbasi A, Calabrò P, Sarandrea A, Rigattieri S, Tomassini F, Sardella G, Zavalloni D, Cortese B, Limbruno U, Tebaldi M, Gagnor A, Rubartelli P, Zingarelli A, Valgimigli M. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - Radiation Dose study (RAD-MATRIX). *Cardiovasc Revasc Med*. 2014 Jun;15(4):209-13. doi: 10.1016/j.carrev.2014.03.010.
30. Valgimigli M, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R; RADAR Investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. *J Am Coll Cardiol*. 2014 May 13;63(18):1833-41. doi: 10.1016/j.jacc.2013.12.043.
31. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). *JACC Cardiovasc Interv*. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008
32. Valgimigli M, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airolidi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. *Am Heart J*. 2013 Nov;166(5):831-8.
33. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). *J Am Coll Cardiol*. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043.
34. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. *Thorax*. 2014 Jan;69(1):80-1. doi: 10.1136/thoraxjnl-2013-203608.
35. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. Coagulation factors

- and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. *Thromb Res.* 2013 Aug;132(2):151-7. doi: 10.1016/j.thromres.2013.06.007
36. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). *Eur Heart J.* 2013 Mar;34(12):909-19. doi: 10.1093/eurheartj/ehs460.
 37. Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. *J Thromb Haemost.* 2013 Jan;11(1):192-4.
 38. Campo G, Napoli N, Serenelli C, Tebaldi M, Ferrari R. Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. *Int J Cardiol.* 2013 Jul 15;167(1):296-7. doi: 10.1016/j.ijcard.2012.09.200.
 39. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martín-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. *Lancet.* 2012 Oct 27;380(9852):1482-90. doi: 10.1016/S0140-6736(12)61223-9
 40. Campo G, Pavasini R, Pollina A, Fileti L, Marchesini J, Tebaldi M, Ferrari R. Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients? *Blood Coagul Fibrinolysis.* 2012 Dec;23(8):680-7. doi: 10.1097/MB013e328355111f.
 41. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dose) trial. *JACC Cardiovasc Interv.* 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006.
 42. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbaheh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation.* 2012 Apr 24;125(16):2015-26. doi:10.1161/CIRCULATIONAHA.111.071589
 43. Campo G, Marchesini J, Fileti L, Tebaldi M, Ferrari R. Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. *J Thromb Haemost.* 2012 Jan;10(1):153-6. doi: 10.1111/j.1538-7836.2011.04563.x.
 44. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. *J Am Coll Cardiol.* 2011 Jun 21;57(25):2474-83. doi: 10.1016/j.jacc.2010.12.047.
 45. Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R. Genetic determinants of on-clopidogrel high platelet reactivity. *Platelets.* 2011;22(6):399-407. doi:10.3109/09537104.2011.579648.
 46. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbaheh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer

	patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J. 2010 Nov;160(5):804-11. doi: 10.1016/j.ahj.2010.07.034 Valgimigli M, <u>Tebaldi M</u>. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. doi: 10.1517/14740338.2010.507189. 47. Valgimigli M, Campo G, <u>Tebaldi M</u>, Monti M, Gambetti S, Scalone A, Parrinello G, Ferrari R; Fabolus Synchro (facilitation through abciximab by dropping infusion Line in patients undergoing coronary stenting. Synergy with clopidogrel at high loading dose regimen) Investigators. Randomized, double-blind comparison of effects of abciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. J Thromb Haemost. 2010 Sep;8(9):1903-11. doi: 10.1111/j.1538-7836.2010.03972.x. 48. Campo G, Fileti L, Valgimigli M, <u>Tebaldi M</u>, Cangiano E, Cavazza C, Marchesini J, Ferrari R. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis. 2010 Oct;30(3):319-31. doi: 10.1007/s11239-010-0457-5. 49. <u>Tebaldi M</u>, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2009 Nov 10;54(20):1900-1. doi: 10.1016/j.jacc.2009.08.009 50. Valgimigli M, Biondi-Zoccai G, <u>Tebaldi M</u>, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. 51. Campo G, Valgimigli M, Frangione A, <u>Tebaldi M</u>, Ferrari R. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemost. 2008 Oct;6(10):1824-6. doi: 10.1111/j.1538-7836.2008.03112.x. 52. Valgimigli M, Campo G, <u>Tebaldi M</u>, Carletti R, Arcozzi C, Ferrari R, Percoco G. Abciximab: a reappraisal of its use in coronary care. Biologics. 2008 Mar;2(1):29-39. 53. Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, <u>Tebaldi M</u>, Luccarelli S, Parrinello G, Ferrari R. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol. 2007 Sep 18;50(12):1132-7.
ATTIVITÀ DI AGGIORNAMENTO (PARTECIPAZIONI A CONGRESSI, ECC...)	1) Partecipazione al “ Corso in interventistica cardiovascolare per giovani cardiologi interventisti” a Genova dal 19 al 21 Ottobre 2010 2) Partecipazione al TCT 2011 a San Francisco dal 7 all’ 11 Novembre 2011 3) Partecipazione al corso “Focus Rota/Cut” all’ Ospedale di Baggiovara (Modena) il 10 Ottobre 2012 4) Presentazione di un poster dal titolo: “1-year outcomes after Tirofiban versus Abciximab infusion in 745 patients with st-segment elevation undergoing primary intervention: insights from the Multistrategy trial” presso ACC 2010 [Atlanta 14-16 Marzo] 5) Presentazione orale dal titolo: “Real-time clopidogrel gain-of-function and loss-of function genotype screening with Nanosphere Verigene 2C19/CBSNucleic Acid” presso Euro-PCR 2011[Parigi 17-20 Giugno] 6) Presentazione orale dal titolo “ Nuove strategie terapeutiche nel trattamento antiaggregante” presso Convegno regionale ANMCO giovani [Mamiano Traversetolo 8 Luglio 2011] 7) Presentazione di un poster dal titolo: “Use of neutrophil gelatinase-associated lipocalin (NGAL)urinary as an early marker of contrast induced acute-kidney injury (CI-AKI) in patients undergoing coronary catheterization” presso il World Congress of Cardiology [Dubai 18-21 Aprile 2012] 8) Presentazione orale dal titolo “Bivalirudina: nuovo Gold standard?” press oil GISE regionale Emilia Romagna –Triveneto [Bologna 6 Maggio 2012]

	9) <i>Presentazione orale dal titolo "Quando è utile aggiungere alla duplice terapia antiaggregante il trattamento con inibitori delle glicoproteine IIb/IIIa?" presso il Convegno regionale ANMCO giovani [Zola Pedrosa 6 Luglio 2012]</i> 10) <i>Relatore al Congresso GISE TOLOVE con una presentazione dal titolo "FFR what else?" [Maggio 2016]</i> 11) <i>Relatore al Congresso Sciacca-Siracusa FFR-OCT and friends con una presentazione dal titolo "Tecniche e indici invasivi preposti per lo studio del microcircolo coronarico" [Giugno 2016]</i> 12) <i>Presentazione di un poster moderato all' American College of Cardiology 2017 dal titolo "Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)"</i> 13) <i>Relatore al congresso Hand of Rayflow and Optowire innovative tools to improve appropriateness con una presentazione dal titolo "Studio del Microcircolo coronarico stato dell' arte" [Giugno 2017 Sciacca]</i> 14) <i>Registrazione di una lezione sulla valutazione funzionale nei laboratori di emodinamica, come modulo di un corso FAD [Agosto 2017]</i> 15) <i>Relatore al EuroPCR2018 con una presentazione dal titolo "Evolving routinary standards in invasive hemodynamic assessment of coronary stenosis: the nationwide Italian SICI-GISE cross-sectional Eris study"</i>
PROFILO LAVORATIVO	- Dal 2013 ad Oggi ho eseguito come primo operatore 1519 Angioplastiche coronariche - Eseguo inoltre come primo operatore impianto del sistema di riduzione del seno coronarico e valvuloplastica aortica

Ferrara, 17 Settembre 2018

Io, Matteo Tebaldi, autorizzo l'uso delle informazioni personali presenti in questo documento in accordo con le leggi vigenti. (D.Lgs. 196/2003)

Dr. Matteo Tebaldi